Idera Pharmaceuticals' stock tanks after AbbVie cuts enrollment early in a PhIb trial

Nicole DeFeudis

Editor

When Idera Pharmaceuticals flunked a Phase III melanoma trial with its Toll-like receptor 9 agonist tilsotolimod back in March, executives clung to the hope …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Idera Pharmaceuticals' stock tanks after AbbVie cuts enrollment early in a PhIb trial

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Vertex makes money from sickle cell therapy Casgevy

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Idera Phar­ma­ceu­ti­cal­s' stock tanks af­ter Ab­b­Vie cuts en­roll­ment ear­ly in a PhIb tri­al

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Idera Pharmaceuticals' stock tanks after AbbVie cuts enrollment early in a PhIb trial